News articles about Perrigo (NYSE:PRGO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Perrigo earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.2176554051957 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Perrigo Trying To Close In On Key Technical Benchmark (finance.yahoo.com)
- Elagolix May Advance the Treatment Paradigm in Women’s Health (finance.yahoo.com)
- Recent Developments for Mylan (finance.yahoo.com)
- Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07pc (newkerala.com)
- Incoming Perrigo CEO Brings Strong Operations Experience (finance.yahoo.com)
PRGO has been the topic of a number of analyst reports. Royal Bank of Canada raised Perrigo from an “underperform” rating to a “sector perform” rating and increased their price objective for the company from $64.00 to $86.00 in a research note on Friday, November 10th. UBS Group reaffirmed a “buy” rating and set a $98.00 price objective (up previously from $84.00) on shares of Perrigo in a research note on Thursday, October 5th. Jefferies Group set a $71.00 price target on Perrigo and gave the stock a “hold” rating in a research note on Sunday, October 29th. Cantor Fitzgerald set a $107.00 price target on Perrigo and gave the stock a “buy” rating in a research note on Saturday, December 16th. Finally, Deutsche Bank raised their price target on Perrigo from $88.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, September 14th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $92.00.
Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.28. Perrigo had a positive return on equity of 11.60% and a negative net margin of 26.28%. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the business earned $1.65 EPS. Perrigo’s revenue for the quarter was down 2.0% compared to the same quarter last year. equities research analysts anticipate that Perrigo will post 4.88 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, December 19th. Stockholders of record on Friday, December 1st were issued a $0.16 dividend. The ex-dividend date was Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.71%. Perrigo’s dividend payout ratio (DPR) is -6.99%.
In other news, EVP John Wesolowski sold 450 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $83.09, for a total value of $37,390.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Todd W. Kingma sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $88.52, for a total value of $132,780.00. Following the completion of the sale, the vice president now owns 19,565 shares of the company’s stock, valued at $1,731,893.80. The disclosure for this sale can be found here. Insiders sold a total of 4,051 shares of company stock valued at $355,370 over the last quarter. Company insiders own 6.90% of the company’s stock.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.